VOLITIONRX LTD — Director's Dealing 2020

Jul 28, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2020-07-27

Reporting Person: Micallef Jacob Vincent (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-07-27	Option (Right to Buy)	$2.5	G	65000	Disposed	2020-08-18	Common Stock (65000)	Indirect
2020-07-27	Option (Right to Buy)	$3	G	65000	Disposed	2020-08-18	Common Stock (65000)	Indirect
2020-07-27	Option (Right to Buy)	$2.5	G	65000	Acquired	2020-08-18	Common Stock (65000)	Direct
2020-07-27	Option (Right to Buy)	$3	G	65000	Acquired	2020-08-18	Common Stock (65000)	Direct
2020-07-27	Option (Right to Buy)	$4	G	55000	Disposed	2021-07-23	Common Stock (55000)	Indirect
2020-07-27	Option (Right to Buy)	$4	G	55000	Acquired	2021-07-23	Common Stock (55000)	Direct

Footnotes

F1: The option to purchase an aggregate of 130,000 shares of Common Stock of VolitionRx Limited (the "Issuer"), was granted to Borlaug Limited ("Borlaug"), a consulting firm, on August 18, 2014 under the Issuer's 2011 Equity Incentive Plan (the "2011 Plan"). Dr. Micallef is a controlling director of Borlaug and has voting and dispositive control over the Common Stock issuable to Borlaug upon the exercise of the option. The option was then transferred by Borlaug to Dr. Micallef on July 27, 2020.

F2: The option to purchase 55,000 shares of Common Stock of the Issuer was granted to Borlaug on July 23, 2015 under the Issuer's 2011 Plan. The option was then transferred by Borlaug to Dr. Micallef on July 27, 2020.